NOT FOR DISTRIBUTION
Header cover image

Shenzhen Chipscreen Biosciences

Market Cap

CN¥15.1b

Last Updated

2021/04/11 09:31 UTC

Data Sources

Company Financials +

Executive Summary

Shenzhen Chipscreen Biosciences Co., Ltd. More Details


Snowflake Analysis

High growth potential with proven track record.

Share Price & News

How has Shenzhen Chipscreen Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 688321 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 688321's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-2.5%

688321

-0.1%

CN Pharmaceuticals

-1.1%

CN Market


1 Year Return

-20.5%

688321

15.8%

CN Pharmaceuticals

28.4%

CN Market

Return vs Industry: 688321 underperformed the CN Pharmaceuticals industry which returned 15.8% over the past year.

Return vs Market: 688321 underperformed the CN Market which returned 28.4% over the past year.


Shareholder returns

688321IndustryMarket
7 Day-2.5%-0.1%-1.1%
30 Day0.9%3.9%1.0%
90 Day1.3%-5.4%-5.8%
1 Year-20.5%-20.5%16.9%15.8%30.4%28.4%
3 Yearn/a25.2%20.7%25.9%19.9%
5 Yearn/a41.6%34.1%23.6%15.5%

Long-Term Price Volatility Vs. Market

How volatile is Shenzhen Chipscreen Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Shenzhen Chipscreen Biosciences undervalued compared to its fair value and its price relative to the market?

486x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 688321's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 688321's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 688321 is poor value based on its PE Ratio (486x) compared to the CN Pharmaceuticals industry average (31.2x).

PE vs Market: 688321 is poor value based on its PE Ratio (486x) compared to the CN market (33.9x).


Price to Earnings Growth Ratio

PEG Ratio: 688321 is poor value based on its PEG Ratio (8.7x)


Price to Book Ratio

PB vs Industry: 688321 is overvalued based on its PB Ratio (10.1x) compared to the CN Pharmaceuticals industry average (2.7x).


Future Growth

How is Shenzhen Chipscreen Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

55.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688321's forecast earnings growth (55.6% per year) is above the savings rate (3.3%).

Earnings vs Market: 688321's earnings (55.6% per year) are forecast to grow faster than the CN market (23.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688321's revenue (48.6% per year) is forecast to grow faster than the CN market (17.9% per year).

High Growth Revenue: 688321's revenue (48.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 688321's Return on Equity is forecast to be low in 3 years time (10.9%).


Past Performance

How has Shenzhen Chipscreen Biosciences performed over the past 5 years?

19.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 688321 has a high level of non-cash earnings.

Growing Profit Margin: 688321's current net profit margins (11.5%) are higher than last year (11.2%).


Past Earnings Growth Analysis

Earnings Trend: 688321's earnings have grown by 19.1% per year over the past 5 years.

Accelerating Growth: 688321's earnings growth over the past year (59.5%) exceeds its 5-year average (19.1% per year).

Earnings vs Industry: 688321 earnings growth over the past year (59.5%) exceeded the Pharmaceuticals industry 10.8%.


Return on Equity

High ROE: 688321's Return on Equity (2.1%) is considered low.


Financial Health

How is Shenzhen Chipscreen Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: 688321's short term assets (CN¥769.1M) exceed its short term liabilities (CN¥146.9M).

Long Term Liabilities: 688321's short term assets (CN¥769.1M) exceed its long term liabilities (CN¥85.6M).


Debt to Equity History and Analysis

Debt Level: 688321's debt to equity ratio (3.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 688321's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 688321's debt is well covered by operating cash flow (161.5%).

Interest Coverage: Insufficient data to determine if 688321's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Shenzhen Chipscreen Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 688321's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 688321's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 688321's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 688321's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 688321's dividend in 3 years as they are not forecast to pay a notable one for the CN market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Xian-Ping Lu

no data

Tenure

Dr. Xian-Ping Lu co-founded Shenzhen Chipscreen Biosciences Ltd. in 2001 and also serves as its Chief Executive Officer, President and Chief Scientific Officer. Dr. Lu serves as a Consultant at Efung Capit...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Shenzhen Chipscreen Biosciences Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shenzhen Chipscreen Biosciences Co., Ltd.
  • Ticker: 688321
  • Exchange: SHSE
  • Founded: 2001
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥15.084b
  • Shares outstanding: 410.00m
  • Website: https://www.chipscreen.com

Number of Employees


Location

  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Biology Incubator Building 2
  • Rooms 601 – 606
  • Shenzhen
  • Guangdong Province
  • 518057
  • China

Listings


Biography

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines that ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 09:31
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.